Combining TRT and GLP-1 Telehealth: What Multi-Vertical Platforms Offer

The intersection of TRT and GLP-1 treatment is increasingly common — men who are using GLP-1 medications for weight loss often have co-occurring low testosterone (which obesity itself suppresses), and men on TRT frequently have metabolic disease that GLP-1 treatment addresses. Here's what multi-vertical telehealth looks like and the clinical considerations for patients navigating both.

Why GLP-1 and TRT co-occur

Obesity suppresses testosterone through two mechanisms: adipose tissue converts testosterone to estradiol via aromatase, and excess body fat suppresses pituitary LH release. Men with obesity and low testosterone who lose significant weight on GLP-1 medications often see testosterone levels recover — partially or fully — without exogenous testosterone. ENDO 2026 data on this: tirzepatide users showed mean testosterone increases of 152 ng/dL at 52 weeks in men with baseline hypogonadism.

Clinical monitoring when combining

Men on both GLP-1 and TRT need coordinated monitoring:

• Hematocrit: TRT elevates hematocrit; GLP-1-driven weight loss improves it; combined effect is unpredictable — quarterly CBC
• PSA: TRT requires baseline and monitoring PSA in men over 40; GLP-1 doesn't add PSA risk independently
• Testosterone levels: as weight loss proceeds on GLP-1, TRT dose may need reduction if endogenous testosterone recovers
• Cardiovascular: TRT carries cardiovascular monitoring requirements; GLP-1 has cardiovascular benefit (SELECT data for sema) — coordinated care, not separate silos